Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies.
Fiche publication
Date publication
novembre 2018
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NERICH Virginie, Dr THIERY-VUILLEMIN Antoine, Dr MOUILLET Guillaume
Tous les auteurs :
Cholley T, Thiery-Vuillemin A, Limat S, Hugues M, Calcagno F, Mouillet G, Anota A, Nerich V
Lien Pubmed
Résumé
Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse. The purpose of this retrospective study was to evaluate cost of illness for 224 patients with mccRCC included in the cohort published by Thiery-Vuillemin et al (Factors influencing overall survival for patients with metastatic clear-cell renal cell-carcinoma in daily practice. Clin Genitourin Cancer 2018; 16:e297-305), and then to determine the explanatory factors of cost of illness.
Mots clés
Clear-cell renal cell carcinoma, Cost of illness, Explanatory factors, Metastatic, Targeted therapies or targeted therapy
Référence
Clin Genitourin Cancer. 2018 Nov 7;: